Abbott's FreeStyle Libre Technology Shows Promising Results for Type 2 Diabetes Management

Abbott's recent FreeDM2 study highlights the benefits of FreeStyle Libre technology for Type 2 diabetes patients using basal insulin. Conducted across 24 UK sites with 303 participants, the study revealed that Libre users had a 0.6% greater reduction in HbA1c and spent 2.5 more hours daily within a healthy glucose range compared to traditional fingerstick methods.

The participant-led approach, using real-time glucose data, empowered patients to make informed lifestyle adjustments. An Italian study corroborated these findings, suggesting wider applicability. This evidence supports calls for broader reimbursement of continuous glucose monitoring systems, especially for basal insulin users.